Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.

Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.

Item

http://www.wikidata.org/entity/Q37105236

Q37105236

about

Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Summary Fibrates for secondary prevention of cardiovascular disease and stroke Dyslipidemia management in primary prevention of cardiovascular disease: Current guidelines and strategies Use of fibrates in the metabolic syndrome: A review Origin and therapy for hypertriglyceridaemia in type 2 diabetes Residual macrovascular risk in 2013: what have we learned?Statins in cardiometabolic disease: what makes pitavastatin different?Omega-3 carboxylic acids monotherapy and combination with statins in the management of dyslipidemia PCSK9 inhibitors - clinical applications The nuances of atherogenic dyslipidemia in diabetes: focus on triglycerides and current management strategies.Treating diabetic dyslipidemia: What have we learnt from recent clinical trials?Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia.Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?Atherogenic dyslipidemia and combination pharmacotherapy in diabetes: recent clinical trials.Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes.Effects of combination lipid therapy in type 2 diabetes mellitus.Non-invited review: prevention of microvascular diabetic complications by fenofibrate: lessons from FIELD and ACCORD.Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.Management of hypertriglyceridemia in the diabetic patient Impact of Fenofibrate on Type 2 Diabetes Patients with Features of the Metabolic Syndrome: Subgroup Analysis From FIELD.Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength?Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid.Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management Combination therapy of statins and fibrates in the management of cardiovascular risk.Lipid control and use of lipid-regulating drugs for prevention of cardiovascular events in Chinese type 2 diabetic patients: a prospective cohort study.Peroxisome proliferator-activated receptors as stimulants of angiogenesis in cardiovascular disease and diabetes.Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor.Plasma triglycerides predict incident albuminuria and progression of coronary artery calcification in adults with type 1 diabetes: the Coronary Artery Calcification in Type 1 Diabetes Study.Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides.Metabolic abnormalities in adult HIV infected population on antiretroviral medication in Malaysia: a cross-sectional survey.Consensus statement on management of dyslipidemia in Indian subjects.Prevalence of hypertension and obesity in patients with type 2 diabetes mellitus in observational studies: a systematic literature review.Apolipoprotein E polymorphisms and postprandial triglyceridemia before and after fenofibrate treatment in the Genetics of Lipid Lowering and Diet Network (GOLDN) Study.Hypertriglyceridemia, Metabolic Syndrome, and Cardiovascular Disease in HIV-Infected Patients: Effects of Antiretroviral Therapy and Adipose Tissue Distribution.PURLs: Add a fibrate to a statin?Saroglitazar for the treatment of hypertrig-lyceridemia in patients with type 2 diabetes: current evidence Hypertriglyceridemia Is Independently Associated with Renal, but Not Retinal Complications in Subjects with Type 2 Diabetes: A Cross-Sectional Analysis of the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study.

P2860

Q21246041-4A64F601-222D-4054-BBCA-3DE1A3C8EB6F Q22241786-FD2AAAC6-A6F9-45FA-B1DC-37427C2A8B82 Q24186376-093B71AD-6987-4320-957E-3C1999F707CC Q26765157-C608125C-D797-4D80-A7B3-13AE493AA7DD Q26765234-BE0FD640-F8C2-46DC-B655-19B8B810BDC6 Q26824004-F82A3CFC-0947-4A84-9662-AA9D026C6940 Q26996039-F0D27DCA-0D9D-4E88-9198-1F044D9C943A Q27010638-776568EF-AD1C-4C85-A4E1-615332441438 Q28076399-D49FB3C0-A106-4D93-95DC-336BE2589F23 Q28079757-DDD68E57-45A9-4E89-9DD2-B925D90478FD Q30357715-42339902-8AAA-42F9-9B7B-0509F051CD27 Q33585474-2915B49F-A0DC-4A79-A652-CADF816C0FF1 Q33590777-DB865C6B-560B-4F0C-9C4A-95AC7DCC90D8 Q33646780-4E8FCE77-A167-42DF-9E2E-A6F10075FBD7 Q33736139-45136628-03D9-4732-B3B9-C867900A2400 Q33776187-749AF38A-ECBB-4A81-9C14-D54ECA01F3CF Q33776194-E8353C7D-5647-45A8-BF38-09822BD81CDC Q33887783-756C82A3-E624-4503-B424-7C0299863DF3 Q33889260-157058B5-574D-4B4E-AB48-F1F244B8C05A Q33901914-F1CC39EB-81D4-4F34-AEE4-2B7FD2FE552C Q33933474-236A1BC8-7E69-48A2-BF5E-00D09A70EB58 Q33935729-4B2830B1-7234-4C6E-A4FE-FDB4D73C0417 Q33940875-395339F0-150B-419E-948D-C495D6587455 Q34023548-E9F327D9-61C5-4849-BE9C-8C9B45570B2A Q34068746-86B18653-B82E-42C7-824D-94B57A217754 Q34181381-767DDE0B-3586-4660-B2D1-2940196575CF Q34305993-43C2DEBD-8D3C-452C-9BA6-F1277041B77B Q34419027-D01B2F8B-5B2D-4C49-810B-4B5BFFAE472A Q34620720-1FDAFB0F-621E-47B4-BCE4-8B0B689F0DCF Q34687470-2FE87E13-D90B-4BE1-81E0-0877E81B646B Q34718616-35AC43EE-2FB3-44A8-9727-9662645C12DA Q34757003-432592D2-AA2E-47A8-A7B4-CE44570AB08B Q34942750-F618FC12-1201-4509-9874-27617EA773A7 Q34980772-0B5CC205-9586-4AC4-A7EF-7D993BAF4A35 Q35003229-6EB5FEC9-6AD3-40A3-9AFB-C78C39D7E220 Q35058300-2F04B9C0-F1F4-4FAD-A2B7-2311D31FE9CA Q35176441-A1718883-25AA-431F-9913-E8AC765750DF Q35247278-40E63997-A412-4460-9CC1-46A580E5C6E3 Q35492306-F8883417-8A9A-4800-BA6A-1D2DD0987231 Q35571714-F604486C-B447-4A5F-A9F8-237C6C965B24

P2860

Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.

Item

http://www.wikidata.org/entity/Q37105236

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Effects of fenofibrate treatme ...... ing in Diabetes (FIELD) study.

@en

Effects of fenofibrate treatme ...... ing in Diabetes (FIELD) study.

@nl

type

Item

label

Effects of fenofibrate treatme ...... ing in Diabetes (FIELD) study.

@en

Effects of fenofibrate treatme ...... ing in Diabetes (FIELD) study.

@nl

prefLabel

Effects of fenofibrate treatme ...... ing in Diabetes (FIELD) study.

@en

Effects of fenofibrate treatme ...... ing in Diabetes (FIELD) study.

@nl

P1476

Effects of fenofibrate treatme ...... ing in Diabetes (FIELD) study.

@en

P2093

Anthony Keech

http://www.w3.org/2001/XMLSchema#string

Chris Pardy

http://www.w3.org/2001/XMLSchema#string

Christian Ehnholm

http://www.w3.org/2001/XMLSchema#string

Dana Tse

http://www.w3.org/2001/XMLSchema#string

Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators

http://www.w3.org/2001/XMLSchema#string

Greg Fulcher

http://www.w3.org/2001/XMLSchema#string

Marja-Riitta Taskinen

http://www.w3.org/2001/XMLSchema#string

Michael D'Emden

http://www.w3.org/2001/XMLSchema#string

Richard O'Brien

http://www.w3.org/2001/XMLSchema#string

Russell Scott

http://www.w3.org/2001/XMLSchema#string

P2860

The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481]

Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies.

Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

Metabolic syndrome--what is the clinical usefulness?

Cardiometabolic risk: a Framingham perspective.

The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study.

P304

493-498

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC08-1543

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2008-11-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23452032

http://www.w3.org/2001/XMLSchema#string

P698

18984774

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

cardiovascular disease

metabolic syndrome

P932

2646035

http://www.w3.org/2001/XMLSchema#string

Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.

about

P2860

P2860

Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P921

P932